Advertisement

Topics

ViaLactia Biosciences Company Profile

05:52 EST 18th February 2018 | BioPortfolio

ViaLactia Biosciences is a biotechnology company operating as a fully owned subsidiary of Fonterra, New Zealand's largest dairy cooperative and the world's largest exporter of dairy products.

At ViaLactia, our goals are the identification, discovery and commercialisation of methods of selection and genes important to the dairy industry, including those affecting pasture grasses, milk production and composition, and animal health. ViaLactia derives value for the dairy farmers of New Zealand by combining Fonterra's knowledge of consumer and commodity markets and their shareholders' best on-farm practices with ViaLactia's in-house research capacities and global alliances with other scientific researchers.

Location

P O Box 109185Newmarket
Auckland
1031
New Zealand

Contact

Phone: 64-9-921-2750
Fax: 64-9-921-2751
Email: info@vialactia.com


News Articles [543 Associated News Articles listed on BioPortfolio]

Harmony Biosciences gains US rights to pitolisant; raises $270 million

USA-based Harmony Biosciences, a part of the Paragon Biosciences corporate family, has acquired the exclusive…

Kuros Biosciences Ltd.: Kuros Biosciences weitet Lizenzabkommen mit Checkmate aus

Schlieren (Zürich), Schweiz, 8. Januar 2018 Kuros Biosciences weitet Lizenzabkommen mit Checkmate aus Kuros Biosciences AG (SIX: KURN) gibt die Ausdehnung des exklusiven Lizenzabkommens mit Checkm...

Apricus Biosciences, Inc.: Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros

Company Evaluating Deficiencies and Potential Path Forward SAN DIEGO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative me...

Kuros Biosciences Ltd.: Kuros Biosciences sichert mögliche Eigenkapitalfinanzierung von bis zu CHF 30 Millionen

Schlieren (Zürich), Schweiz, 22. November 2017 Kuros Biosciences sichert mögliche Eigenkapitalfinanzierung von bis zu CHF 30 Millionen Kuros Biosciences (SIX: KURN) gibt den Abschluss eines Standb.....

Apricus Biosciences, Inc.: Apricus Biosciences to Present at the 2017 BIO Investor Forum

SAN DIEGO, 2017-10-10 13:00 CEST (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced...

Kuros Biosciences Ltd.: Kuros Biosciences gibt Nachfolge im Management bekannt

Schlieren (Zürich), Schweiz, 14. Dezember 2017 Kuros Biosciences gibt Nachfolge im Management bekannt Kuros Biosciences AG (SIX: KURN) gibt die Ernennung von Michael Grau zum Chief Financial Offic...

AB Biosciences & Shire Enter License Agreement

For AB Biosciences' pan receptor interacting molecule (PRIM) program

Shire plc: AB Biosciences and Shire Enter Into Agreement for Development and Commercialization of AB Biosciences' PRIM Program

AB Biosciences and Shire Enter Into Agreement for Development and Commercialization of AB Biosciences' PRIM Program for Potential Treatment of Autoimmune Diseases and Other Immune-Mediated Disorde...

Drugs and Medications [13 Associated Drugs and Medications listed on BioPortfolio]

Naturally nova scotia hand sanitizer [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Natelle one [Azur Pharma, Inc.]

Natelle OneRx Prenatal Vitamin & Plant-Based DHA Now with 28 mg Iron

Natelle one [Azur Pharma, Inc.]

Natelle®OneRx Prenatal Vitamin & Plant-Based DHA

PubMed Articles [75 Associated PubMed Articles listed on BioPortfolio]

Draft Genome Sequences of Trichophyton rubrum CMCC(F)T1i and Trichophyton violaceum CMCC(F)T3l by Illumina 2000 and Pacific Biosciences.

One strain of Trichophyton rubrum CMCC(F)T1i (=CBS 139224) isolated from onychomycosis and one strain of Trichophyton violaceum CMCC(F)T3l (=CBS 141829) isolated from tinea capitis in China were whole...

Introduction.

Amnesia and criminal responsibility.

Back cover.

Front cover.

Clinical Trials [7 Associated Clinical Trials listed on BioPortfolio]

HepaStem Long-Term Safety Registry

All patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HHALPC during a previous interventional clinical study conducted by Promethera Bi...

Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy

The purpose of this research is to determine if a subject's own bone marrow tissue can help regenerate bone in the area of his/her jaw where a tooth has been removed using Tissue Repair Ce...

Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data

We seek to improve the predictive accuracy of the nomogram to predict survival for patients with castrate mets disease through the addition of pathological data, the results of automated m...

Validation of Decipher Test in African American Men With Prostate Cancer - VANDAAM

The primary purpose of this study is to determine whether a tumor test recently developed by GenomeDx Biosciences known as Decipher® can predict aggressive prostate cancer with the same a...

Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic

The purpose of the expanded access program is to allow physicians to provide treatment with investigational drug, AB-PA01, for patients with serious or immediately life-threatening Pseudom...

Companies [345 Associated Companies listed on BioPortfolio]

ViaLactia Biosciences

ViaLactia Biosciences is a biotechnology company operating as a fully owned subsidiary of Fonterra, New Zealand's largest dairy cooperative and the world's largest exporter of dairy products.At ViaLac...

ViaLactia Biosciences Ltd

ViaLactia’s genomics research programs are organised into separate but interdependent platforms. The major fields of interest are in Bovine, Forage and microbe genomes which are all dependent on our...

Hydra Biosciences, Inc.

Hydra Biosciences is a privately-held biopharmaceutical company based in Cambridge, Massachusetts, and develops drugs to treat pain, inflammation, anxiety and other diseases using...

Leadiant Biosciences, Inc.

Leadiant Biosciences, Inc. (formerly Sigma-Tau Pharmaceuticals, Inc.) is a U.S.-based, wholly owned subsidiary of Leadiant Biosciences S.p.A., a research-based pharmaceutical comp...

JeNu Biosciences

JeNu Biosciences was founded in 2008 by a team of ultrasound scientists, medical doctors and beauty executives and is currently led by Wayne Wager, CEO. JeNu Biosciences is a Seat...

More Information about "ViaLactia Biosciences" on BioPortfolio

We have published hundreds of ViaLactia Biosciences news stories on BioPortfolio along with dozens of ViaLactia Biosciences Clinical Trials and PubMed Articles about ViaLactia Biosciences for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ViaLactia Biosciences Companies in our database. You can also find out about relevant ViaLactia Biosciences Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record